The regulatory landscape

Pharmaceuticals is among the most heavily scrutinised industries worldwide. In China, July 2023 saw fourteen ministries — led by the National Health Commission — launch a one-year, nationwide anti-corruption campaign of unprecedented scale and severity.

The enforcement matrix

Enforcement bodyLegal basisMeasures
Market regulator (SAMR)Anti-Unfair Competition Law, Art. 7Administrative investigation, fines (up to CNY 3,000,000), confiscation of unlawful gains.
Public securityCriminal Law Art. 163, 164, 385–393Criminal investigation, arrest and referral for prosecution.
Discipline inspection & supervisionSupervision Law; party discipline rulesDisciplinary and supervisory review of public officials such as hospital directors and department heads.
Health authority (NHC)"Nine Prohibitions" on medical-industry conductIndustry supervision, suspension and licence revocation.
Healthcare security (NHSA)Regulations on Supervision of Healthcare Security Fund UseCredit ratings — "serious" and "especially serious" breaches suspend products from procurement platforms; fund recovery.
Tax authorityTax Collection Administration LawAudits of false invoices and fictitious costs that fund bribes.

The legal definition of commercial bribery

Administrative bribery

Anti-Unfair Competition Law Art. 7 prohibits operators from using money, property or other means to bribe any of the following to win a transaction or competitive advantage:

  • Employees of the counterparty
  • Persons or entities entrusted by the counterparty
  • Persons or entities able to influence the transaction through position or influence

The key distinction: open, book-recorded discounts to the counterparty, or openly accounted commissions to intermediaries, are not commercial bribery. Any concealed or off-book payment falls within the definition.

Criminal liability

OffenceApplies toStatutory penalty
Bribery of non-state functionaries (Art. 164)Bribing doctors/managers of private hospitals and clinicsAbove CNY 60,000: up to 3 years plus fine; above CNY 2,000,000: 3–10 years plus fine.
Acceptance of bribes by non-state functionaries (Art. 163)Doctors/managers of private institutions taking bribesMirrors the above.
Bribery (Art. 389–390)Bribing doctors/managers of public hospitals (state functionaries)Up to 5 years; serious cases (above CNY 1,000,000 or major loss): 5–10 years; especially serious (above CNY 5,000,000): 10+ years or life.
Acceptance of bribes (Art. 385–386)Public-hospital doctors/managers taking bribesAbove CNY 30,000: up to 3 years; above CNY 200,000: 3–10 years; above CNY 3,000,000: 10+ years, life or death.
Unit bribery (Art. 393)A company bribing state functionariesFine on the company; up to 5 years for responsible individuals.

The key 2023 shift — "prosecute both sides": enforcement now targets giver and receiver alike. Historically the receiver (doctors) bore the brunt; the pharma side was rarely pursued. Since 2023, the Central Commission for Discipline Inspection has explicitly demanded "investigate both bribery and acceptance", and many pharma executives, regional managers and medical reps have been investigated in parallel. Companies can no longer assume "it only reaches the doctor's end".

High-risk scenarios and compliance boundaries

Kickbacks in academic promotion

  • Speaker fees — the traffic lights: lawful when a doctor genuinely delivers an academic presentation at fair market rates, with a written speaker agreement, proper tax withholding and book-recorded payment. Unlawful when speakers are "on paper only", fees are grossly inflated, or fees are used to reward prescribing volume.
  • Meeting sponsorship: sponsorship should be public-interest and non-exclusive, paid to the host institution or organiser — not directly to attending physicians.
  • Travel arrangements: reasonable and moderate — economy flights, standard hotels, no tourism components.

"Sales kickbacks" — a red line

Paying doctors a fixed percentage of sales volume is the classic commercial bribery model and the top enforcement target. In the new "both sides" climate, every participant from head office down to the rep faces prosecution risk.

Disguised bribes via "research funds" and "donations"

  • High "research fees" for clinical or post-market studies that are really prescribing incentives
  • "Equipment donations" or "department building fees" in exchange for formulary or procurement commitments
  • "Patient education" or "disease awareness" events that are disguised tourism

Building a compliance program — from firefighting to prevention

Seven pillars

  1. Leadership commitment and culture: a board/CEO-signed compliance policy.
  2. Risk assessment: regular bribery risk assessment of every HCP-facing activity.
  3. Written policies and SOPs: covering speaker fees, sponsorship, gifts, hospitality, travel and donations.
  4. Third-party due diligence: screening CROs, CSOs, market-research and event companies — the "grey channel" hotspots.
  5. Training: mandatory annual training for all HCP-facing staff.
  6. Reporting channels: independent, anonymous hotlines with anti-retaliation protection.
  7. Internal investigation and remediation: prompt, thorough investigation of red flags with corrective and disciplinary action.

Our program-building services

  • Compliance "health checks" of existing processes and transactions
  • Tailored policy manuals and SOPs covering all seven pillars
  • Standardised third-party due-diligence workflows for CSOs/CROs
  • Layered, scenario-based compliance training
  • Mock audits that simulate an enforcement lens

Crisis response when under investigation

Administrative

  • Dawn-raid contingency plans and staff training on lawful responses to entry, questioning and seizure
  • Assessment of enforcement authority boundaries and protection of legal rights
  • Legal rights during administrative interviews

Criminal

  • Pre-filing intervention: risk assessment and compliance remediation (a strong compliance program is a key factor in non-prosecution)
  • Bail applications after filing
  • Defence submissions at the review-for-prosecution stage
  • Full defence at trial, including criminal-compliance non-prosecution mechanisms successfully used in pharma bribery cases

Cross-border: FCPA and China law together

Multinationals in China — and Chinese companies planning overseas listings — must satisfy multiple regimes simultaneously:

  • US FCPA: applies to US-listed companies and their global subsidiaries, prohibiting bribes to foreign officials — including China public-hospital doctors, treated as "foreign officials" under the FCPA. Penalties can reach hundreds of millions of dollars.
  • UK Bribery Act: even broader — prohibiting both official bribery and commercial bribery (including of private-sector medical staff).
  • China's Anti-Unfair Competition Law and Criminal Law: as described above.